[期刊]
  • 《Expert opinion on drug safety》 2022年21卷7/12期

摘要 : IntroductionNeo/adjuvant therapy for early-stage breast cancer has become increasingly common in the last few decades; as a consequence, the number of breast cancer survivors experiencing often debilitating long-term side effects ... 展开

相关作者
相关关键词